Analysts expect XOMA Co. (NASDAQ:XOMA) to announce ($0.52) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for XOMA’s earnings, with estimates ranging from ($0.57) to ($0.46). XOMA reported earnings of ($2.89) per share during the same quarter last year, which would indicate a positive year over year growth rate of 82%. The firm is expected to issue its next earnings results on Thursday, March 15th.
On average, analysts expect that XOMA will report full-year earnings of ($0.09) per share for the current year, with EPS estimates ranging from ($0.45) to $0.28. For the next fiscal year, analysts forecast that the company will post earnings of ($0.42) per share, with EPS estimates ranging from ($0.89) to ($0.13). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow XOMA.
A number of equities research analysts have recently issued reports on XOMA shares. Zacks Investment Research raised shares of XOMA from a “sell” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Tuesday, October 17th. TheStreet raised shares of XOMA from an “e+” rating to a “c-” rating in a report on Wednesday, November 29th. HC Wainwright set a $38.00 target price on shares of XOMA and gave the company a “buy” rating in a report on Tuesday, November 14th. Finally, Wedbush reaffirmed a “buy” rating and issued a $33.00 target price on shares of XOMA in a report on Tuesday, December 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. XOMA currently has an average rating of “Buy” and an average target price of $38.33.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can acquired a new position in XOMA in the 4th quarter valued at about $138,000. Acadian Asset Management LLC acquired a new position in XOMA in the 4th quarter valued at about $152,000. Wells Fargo & Company MN grew its stake in XOMA by 4,288.9% in the 4th quarter. Wells Fargo & Company MN now owns 8,295 shares of the biotechnology company’s stock valued at $295,000 after buying an additional 8,106 shares during the last quarter. Alps Advisors Inc. acquired a new position in XOMA in the 4th quarter valued at about $321,000. Finally, Goldman Sachs Group Inc. acquired a new position in XOMA in the 4th quarter valued at about $328,000. Institutional investors and hedge funds own 34.04% of the company’s stock.
Shares of XOMA (XOMA) traded up $0.63 during mid-day trading on Wednesday, hitting $27.41. 160,802 shares of the stock were exchanged, compared to its average volume of 160,848. The company has a debt-to-equity ratio of 3.53, a quick ratio of 3.45 and a current ratio of 3.45. The company has a market cap of $218.10, a PE ratio of -3.82 and a beta of 2.95. XOMA has a 12 month low of $4.50 and a 12 month high of $37.25.
COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/14/zacks-brokerages-anticipate-xoma-co-xoma-to-post-0-52-eps.html.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Get a free copy of the Zacks research report on XOMA (XOMA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.